Lupus, a chronic autoimmune disease that can affect multiple organs, has long challenged scientists seeking a clear cause. Although effective treatments exist, the underlying mechanisms that trigger the disease have remained unclear.
New research published in Science Translational Medicine provides strong evidence that Epstein-Barr virus (EBV)—one of the most common viruses worldwide—may be a major driver of lupus by disrupting normal immune function.
A Ubiquitous Virus With Potential Autoimmune Impact
EBV infects roughly 95% of people at some point in their lives. Many experience no symptoms, while others develop infectious mononucleosis. After initial infection, the virus remains in the body in an inactive state, primarily within B cells, a type of white blood cell responsible for producing antibodies.
Scientists have suspected for decades that EBV plays a role in certain autoimmune conditions, including multiple sclerosis. The new study adds to this evidence by describing a detailed biological pathway through which EBV may trigger lupus.
New Findings Identify a Mechanistic Link
Dr. William Robinson of Stanford University, senior author of the study, reports that lupus patients have significantly more EBV-infected B cells than people without the disease—approximately 25 times more. The research team found that EBV can reprogram these B cells to produce antinuclear antibodies, a hallmark of lupus. These antibodies mistakenly target the body’s own cells, fueling widespread inflammation and tissue damage.
Robinson and his colleagues believe this newly identified pathway may represent a central mechanism in lupus. However, experts caution that more research is needed before concluding that EBV accounts for every case. Hoang Nguyen of the Lupus Research Alliance emphasized that while the findings are compelling, they may not apply uniformly across all patients.
Why EBV Triggers Disease in Some but Not Others
Despite EBV’s near-universal prevalence, only a small proportion of infected individuals develop autoimmune disease. Researchers suspect that genetics, hormonal factors, and immune cell behavior may influence vulnerability. Prior studies have shown that people with lupus often exhibit imbalances in certain T cells—cells that regulate immune responses—which could interact with the EBV-related pathway described in the new research.
Robinson noted that variations in EBV strains might also help explain why only some individuals progress to disease, though further investigation is needed.
Implications for Treatment and Prevention
Current lupus therapies, including corticosteroids and other immunomodulatory medications, aim largely to reduce inflammation and manage symptoms. The new findings suggest the possibility of more targeted treatments designed to eliminate or neutralize EBV-infected B cells specifically.
Even more transformative, researchers say, could be the development of an EBV vaccine. Several vaccine candidates are already in clinical trials. If effective, such a vaccine could prevent primary EBV infection and potentially reduce the risk of lupus and other autoimmune conditions linked to the virus.
Dr. Anca Askanase of Columbia University, who was not involved in the study, said the growing evidence highlights an urgent need for preventive strategies. “If we now better understand how this virus contributes to autoimmune diseases, it’s time to figure out how to prevent it,” she said.
Related topics
